chemie.pr-Presseportal: Abbott Laboratories - Wissenschaftler von Abbott haben ...
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
13.05.2008 16:00:07
Abbott Laboratories: Barcelona, Spain (ots/PRNewswire) - - Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS Long-term data presented for the first ...
Lesen Sie hier weiter... |
Drucken |
PDF
Ähnliche Artikel
- FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
- XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
- Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials
- Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First'Real World, All Comers' Clinical Study
- Der mit Perikard ummantelte Over-and-Under(R)-Stent wird jetzt in England benutzt und lässt sich hervorragend einsetzen
- Abbott Study Shows Investigational Heat-Stable Norvir(R) Tablet Provides Similar Drug Levels to Current Norvir Capsule
- Abbott Recognized on Dow Jones Sustainability Index (DJSI) for Fourth Consecutive Year
- Wissenschaftler von Abbott stellen neuen Ansatz zur Behandlung der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung vor
- Abbott Launches Next-Generation StarClose(R) SE Vascular Closure System
- Coversyl(R) Protects Hypertensive Patients Against New-Onset Diabetes
XIENCE(TM) V DRUG ELUTING STENT FROM ABBOTT OUTPERFORMS MARKET-LEADING ...
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years Barcelona, Spain (ots
ots.at: das APA-OTS-Portal für multimediale Presseaussendungen
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major.Adverse Cardiac Events at Two Years = 13.05.2008 / 15:38
SCOUTY.de - Suchergebnis
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
ITGI Medical erhält CE-Kennzeichnung für AneuGraft(R), den zweiten, mit ...
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years